Retatrutide: What the Evidence Actually Shows

Retatrutide is a triple agonist still in development at Eli Lilly: it switches on three receptors at once — glucagon alongside GIP and GLP-1 — where tirzepatide reaches two of them and semaglutide only one. The reported weight-loss numbers are the largest in the field. It is also not approved, cannot be prescribed, and is sold anyway across a gray market with no pharmacy behind it.

The number people repeat is 28.7%. It is real, and it does not mean what most pages citing it imply, because of where it comes from. That distinction is the most useful thing on this page.

Two numbers, two very different kinds of evidence

Searching PubMed for TRIUMPH-4 results returns nothing. What is indexed is the design of the TRIUMPH program — the protocol paper describing how the trials are set up (PMID 41090431).^[2] The results themselves exist so far as a corporate statement.

Worth noting too: the phase 2 figure comes from an arm of 81 people. It is a strong signal and a small one, and phase 2 effects routinely shrink at scale.

The number sellers do not quote

The same December 2025 release reported a side effect that rarely appears in the enthusiastic coverage: dysesthesia — abnormal, often unpleasant skin sensation such as burning, prickling or numbness — in 20.9% of the 12 mg arm and 8.8% of the 9 mg arm, against 0.7% on placebo. Lilly described the events as generally mild and rarely leading to discontinuation.

That is roughly one in five people at the top dose reporting something the GLP-1 drugs on the market do not commonly produce. ⚠ It is the kind of finding that phase 3 exists to surface, and it is exactly what you do not get when you buy a molecule outside the trial system: nobody is recording what happens to you, and nobody is comparing it against a placebo arm.

Why you can buy it anyway

You can buy it today, at scale. The vials arrive marked not for human consumption and described as laboratory material. That phrase is a legal device: it is meant to place the sale outside drug regulation while the surrounding marketing addresses people who plainly intend to inject it.

• No prescriber. Nobody has assessed whether this is appropriate for you, and nobody is monitoring what happens.
• No pharmacy. Not a 503A, not a 503B, no state licensure, no USP <797> sterile compounding standard, no inspection history to look up.
• No way to know what is in the vial. Identity, purity, concentration and sterility are all unverified. A certificate of analysis supplied by the seller is a document the seller produced.
• No accountability if it goes wrong. The disclaimer on the label is precisely the point of the disclaimer.
• No dose established for humans. The phase 3 program is still running — that is what it is for.

If you want what retatrutide promises

The honest position is that the approved drugs already deliver a large part of it. Tirzepatide reported 20.9% at 72 weeks in a phase 3 trial of 2,539 people, published and scrutinized, and you can be prescribed it tomorrow with a clinician and a pharmacy attached.^[3] Retatrutide's published figure is 24.2% from an 81-person phase 2 arm.

If retatrutide is approved, it will be prescribable, monitored and covered by the same accountability every other drug has. That is worth waiting for. Our comparison of retatrutide against Zepbound sets the two side by side, and the research-chemical market covers what buying outside the system actually involves.

Common questions